Low-Dose Aspirin May Reduce Colorectal Cancer Recurrence
Recent research indicates that common over-the-counter medications, particularly low-dose aspirin, could significantly lower the chances of colorectal cancer returning. A study out of Sweden highlights that this approach may be especially beneficial for patients whose tumors harbor specific genetic mutations.
The study, conducted by researchers from Karolinska Institutet and Karolinska University Hospital, tracked over 3,500 cancer patients from multiple hospitals across Sweden, Norway, Denmark, and Finland—all of whom underwent surgery to remove their tumors.
Among those with a particular genetic mutation related to the PIK3 signaling pathway, half of the participants received 160 milligrams of daily aspirin, while the other half were given a placebo. Remarkably, after three years, the aspirin group experienced a 55% drop in the risk of cancer recurrence compared to their counterparts.
Dr. Anna Martyling, a senior author from the study, emphasized that this randomized trial provides the first concrete evidence showing how low-dose aspirin impacts colorectal cancer patients, noting that it applies to over a third of individuals who have had their tumors surgically removed.
Martyling pointed out that the effect seemed more pronounced in women, suggesting that further investigation is warranted. The research findings were documented in the New England Journal of Medicine.
Despite its common use as a pain reliever and anti-inflammatory, aspirin is also utilized to help prevent blood clots. Its accessibility and low cost make it a feasible option compared to newer, more expensive cancer therapies.
Dr. Marc Siegel, a senior medical analyst who did not participate in the study, remarked on the implications of aspirin in reducing growth factors related to cancer. He reiterated the need for additional research to fully understand the potential benefits.
However, like many clinical studies, this one had limitations. For instance, it didn’t include patients over the age of 80, and a longer follow-up period is necessary to evaluate overall survival rates better. Researchers acknowledged potential side effects, such as stomach issues and bleeding risks, highlighting that individuals with pre-existing conditions should be cautious.
Experts also underscored the importance of assessing the risks and advantages of aspirin use tailored to individual patients, rather than making broad recommendations just yet. The study was partially funded by the Swedish Research Council and the Swedish Cancer Society.
Ultimately, the outcomes of this research could have a substantial impact on treatment protocols, especially in regions with limited access to costly modern therapies. If adopted widely, these strategies could potentially save thousands of lives annually.
